This information is for healthcare professionals based in EU countries only.
Are you a healthcare professional?
FCS is a debilitating disease with a high risk of pancreatitis due to high triglyceride (TG) levels over a prolonged time.2,3
Observational data suggest that the incidence of acute pancreatitis increases 3% for every increment of 100 mg/dl in TG levels > 1000 mg/dl; therefore a decrease in TG levels to any extent below this threshold may result in a decrease in the risk of acute pancreatitis.4
In the APPROACH study, Waylivra significantly reduced mean fasting TG levels by 77% at 3 months in patients with FCS. The incidence of pancreatitis was numerically lower in the Waylivra group compared with placebo1,4
Results from the open label extension (OLE) study** showed sustained reduction in plasma TG levels up to 156 weeks*** with no new safety signals. These results support the long-term use of Waylivra in patients with FCS.5
With proactive monitoring, Waylivra has a manageable safety profile5
Waylivra is a self-administered injection delivered in a single-use prefilled syringe1
*by EMA
**This study had some limitations, including those inherent with an open-label study design. Without a placebo or non-treatment group, assessing whether an actual. Reduction in acute pancreatitis risk occurred is challenging.
***Total number of weeks from both APPROACH and COMPASS study.
This information is for healthcare professionals based in EU countries only.
Are you a healthcare professional?